Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: twistbioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $60.00 | Outperform | Wolfe Research |
| 6/4/2024 | $53.00 | Buy | Guggenheim |
| 1/17/2024 | $25.00 → $45.00 | Neutral → Buy | Goldman |
| 9/27/2023 | $27.00 | Buy | Berenberg |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 1/3/2023 | $28.00 → $36.00 | In-line → Outperform | Evercore ISI |
| 3/2/2022 | Outperform | Cowen | |
| 2/7/2022 | $130.00 → $75.00 | Overweight | Barclays |
| 2/7/2022 | $110.00 → $70.00 | Market Perform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato